Spirit II Results Support Boston Scientific’s Drug-Eluting Stent Platform
April 1, 2008 – Boston Scientific welcomed results from Abbott’s prospective, randomized, single blind, two-year SPIRIT II Trial, comparing the safety and efficacy of the XIENCE V (PROMUS) Everolimus-Eluting Coronary Stent and Boston Scientific’s TAXUS Express Paclitaxel Eluting Coronary Stent System in 300 patients in Europe.
The PROMUS Stent is a private-label XIENCE V manufactured by Abbott and distributed by Boston Scientific.
The results, presented yesterday at ACC 2008, demonstrated no numerical differences between the XIENCE V and the TAXUS in their angiographic outcomes. The cardiac death rate at two years for the XIENCE V was .5 percent and for the TAXUS was 1.4 percent. Myocardial infarction (MI) rates at two years for the XIENCE V and TAXUS were 2.8 percent and 5.5 percent, respectively.
The XIENCE V (PROMUS) Stent is currently pending approval by the FDA, which is expected to occur in the first half of 2008, said Boston Scientific.
For more information: www.bostonscientific.com
More like this
- PROMUS, First-Generation TAXUS Express Stents Perform Strongly in SPIRIT III Trial
- Boston Scientific’s Stents Report Low Thrombosis at One Year
- ACC2: SPIRIT III Proven Safe and Effective, Boston Scientific Announces
- Boston Scientific Offers PROMUS Everolimus-Eluting Coronary Stent System
- Boston Scientific, Abbott Offer New Everolimus-Eluting Coronary Stents